Mesoblast

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Trading Performance

Basic Candlestick

Score

-0.55

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
SHORT 112 4.6 0.38% 0.60% 4.8% -3.0% -10.3%
LONG 113 3.8 0.36% 0.53% 3.9% -2.6% -43.8%

Summary

Technical Analysis

Mesoblast (MSB.AX)


Indicator:

SHORT BLACK CANDLE


Last Signal:

BEARISH


Trading: SELL @ $1.41
Signal Strength: WEAK
Recommendation:

Indicator MUST BE USED in additional to another technical indicator to confirmation for trading position. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This Japanese candlestick indicator can provide guidance on the short term battle between sellers and buyers from the companies recent trading.


Mesoblast (ASX:MSB) has formed a Short Black candlestick. This means, MSB has limited price movement derived from weak selling pressure. Given the limited timeframe in which signal has formed, further confirmation is required through volume and additional technical indicators.



This candlestick implies a relatively weak selling pressure with a limited price movement.

Calculation: Short Black Candlestick:
1) The body of the candlestick is black and small;


PROFILE: Mesoblast (MSB.AX)


Stock Exchange: ASX
Company: Mesoblast
Ticker Codes: | MSB.AX | ASX:MSB |

About Mesoblast (ASX:MSB):

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Top 10:

Basic Candlestick

Download
Company Close Change(%) Volume Value Signal
BFC Beston Global Food 0.11 5 372,431 0 BEARISH
UOS United Overseas Australia 0.76 3.4 34,821 0 BEARISH
RRL Regis Resources 5.16 2 3,902,408 0 BEARISH
RMS Ramelius Resources 0.76 1.3 3,996,500 -1 BEARISH
QMS Qms Media 0.82 1.2 324,866 0 BEARISH
EVN Evolution Mining 4.34 0.9 11,923,929 0 BEARISH
SLK Sealink Travel 3.7 0.8 13,691 0 BEARISH
IFM Infomedia 1.7 0.6 136,408 -1 BEARISH
CNI Centuria Capital 1.81 0.6 157,492 0 BEARISH
ENN Elanor Investors 1.82 0.3 424,474 0 BEARISH